SCHEMBL6656595

SCHEMBL6656595

CCC1CC(=O)N(Cc2cccc(NC(=O)c3cccs3)c2)N=C1c1ccc(OC)c(OC)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
ACKR3 P25106 5/20 0.47
MEN1 O00255 3/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
ALDH1A1 P00352 2/20 0.46
LMNA P02545 1/20 0.46
TP53 P04637 1/20 0.46
GAA P10253 1/20 0.46
PDE4A P27815 5/20 0.45
PDE4B Q07343 5/20 0.45
PDE4C Q08493 5/20 0.45
PDE4D Q08499 5/20 0.45
MET P08581 1/20 0.45
PDE3B Q13370 1/20 0.45
PDE3A Q14432 1/20 0.45
MAPT P10636 2/20 0.44
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6841799 0.93 PDE4A (0.49) KMT2AL3MBTL1ACKR3MEN1NPC1
SCHEMBL6656699 0.92 KMT2A (0.51) KMT2AL3MBTL1MEN1NPC1RAB9A
SCHEMBL6654929 0.88 KMT2A (0.46) KMT2AL3MBTL1MEN1NPC1RAB9A
SCHEMBL6654537 0.88 KMT2A (0.46) KMT2AL3MBTL1MEN1NPC1RAB9A
SCHEMBL6674499 0.88 PDE4B (0.47) L3MBTL1ACKR3SMN1; SMN2LMNAPDE4A
SCHEMBL6654735 0.87 KMT2A (0.45) KMT2AL3MBTL1MEN1NPC1RAB9A
SCHEMBL6662641 0.87 PDE4D (0.49) PDE4APDE4BPDE4CPDE4DMET
SCHEMBL6657674 0.87 PDE4D (0.49) KMT2AMEN1PDE4APDE4BPDE4C
SCHEMBL6659625 0.87 PDE4D (0.51) PDE4APDE4BPDE4CPDE4DMET
SCHEMBL6661995 0.87 KMT2A (0.53) KMT2AMEN1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040235845-A1 Use of phosphodiesterase iv inhibitors MERCK PATENT GESSELSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2004-11-25 US disclosed
EP-1435958-A1 USE OF PHOSPHORODIESTERASE IV INHIBITORS MERCK PATENT GmbH (DE) 2004-07-14 EP disclosed
WO-2003032993-A1 USE OF PHOSPHORODIESTERASE IV INHIBITORS MERCK PATENT GMBH (DE) 2003-04-24 WO disclosed
US-5859008-A Arylalkyl diazinones MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1999-01-12 US disclosed
EP-0763534-A1 Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors MERCK PATENT GmbH (DE) 1997-03-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235845-A1 Use of phosphodiesterase iv inhibitors PDE4A, PDE3A, PDE3B KMT2A 3056/4885L3MBTL1 4206/4885ACKR3 662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.